![]() Through a prospective randomized study of production allograft, we were able to validate that the D-Min™ process yields a consistently osteoinductive product. Controls in the D-Min™ process eliminate many of the variables that can affect the osteoinductivity of demineralized bone matrix. Aseptic processing methods versus those employing ethylene oxide or terminal sterilizationĪt Medtronic, we use our proprietary D-Min™ process to demineralize the allograft tissue that goes into the different Grafton™ DBM forms.Application of defatting agents such as ethanol.Acid concentration and soak time for demineralization.Our aseptically processed fibers have some of the highest osteoinductive scores † on the market and this interconnected mesh of fibers enhances the osteoconductive potential of the product by providing a path for cellular infiltration.īecause allograft tissue processing, including demineralization, has evolved over time and is performed by numerous processors, it is important to recognize that not all demineralization processes are alike. Medtronic was the first to market with a fiber based DBM. And a fiber technology proven to be osteoconductive in a preclinical outcomes study.Validated process consistently produces an osteoinductive finished allograft. ![]() Proven in prospective clinical studies. ![]()
0 Comments
Leave a Reply. |